Journal ArticleDOI
Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.
Reads0
Chats0
TLDR
The incidence of thromboembolic complications and vascular mortality were significantly lower in the warfarin group than in the aspirin and placebo groups, which did not differ significantly.About:
This article is published in The Lancet.The article was published on 1989-01-28. It has received 1636 citations till now. The article focuses on the topics: Warfarin & Stroke.read more
Citations
More filters
Journal ArticleDOI
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.
TL;DR: The data suggest that the elderly are particularly vulnerable to stroke when atrial fibrillation is present, and the effects of hypertension, coronary heart disease, and cardiac failure on the risk of stroke became progressively weaker with increasing age.
Journal ArticleDOI
Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation
TL;DR: An updated meta-analysis of all currently available randomized trials that extends observations about the efficacy and safety of antithrombotic therapies for preventing stroke in patients who have atrial fibrillation is presented.
Journal ArticleDOI
Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.
Emelia J. Benjamin,Daniel Levy,Sonya M. Vaziri,Ralph B. D'Agostino,Albert J. Belanger,Philip A. Wolf +5 more
TL;DR: In addition to intrinsic cardiac causes such as valve disease and congestive heart failure, risk factors for cardiovascular disease also predispose to atrial fibrillation.
Journal ArticleDOI
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Valentin Fuster,Lars Rydén,David S. Cannom,Harry J.G.M. Crijns,Anne B. Curtis,Kenneth A. Ellenbogen,Jonathan L. Halperin,Jean-Yves Le Heuzey,G. Neal Kay,James E. Lowe,S. Bertil Olsson,Eric N. Prystowsky,Juan Tamargo,Samuel Wann,Sidney C. Smith,Alice K. Jacobs,Cynthia D. Adams,Jeffery L. Anderson,Elliott M. Antman,Sharon A. Hunt,Rick A. Nishimura,Joseph P. Ornato,Richard L. Page,Barbara Riegel,Silvia G. Priori,Jean Jacques Blanc,Andrzej Budaj,A. John Camm,Veronica Dean,Jaap W. Deckers,Catherine Despres,Kenneth Dickstein,John Lekakis,Keith McGregor,Marco Metra,João Morais,Ady Osterspey,José Luis Zamorano +37 more
TL;DR: Sidney C. Smith, Jr., MD, FACC, FAHA, FESC, Chair; Alice K. Jacobs, MD, FAC, FAH, Vice-Chair; Cynthia D. Adams, MSN, APRN-BC, FAGA; Jeffery L. Anderson, MD.
Journal ArticleDOI
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
TL;DR: Guyatt et al. as mentioned in this paper presented the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) and provided specific management recommendations for the first 1 or 2 days for most individuals.
References
More filters
Journal ArticleDOI
Inhibition of platelet function by low-dose plain and micro-encapsulated acetylsalicylic acid.
TL;DR: It is concluded that significant inhibition of platelet activity may be achieved by low-dose ASA treatment with micro-encapsulated as well as with plain formulations.
Related Papers (5)
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
Mg Ceravolo,Leandro Provinciali +1 more